The focus of this study was to enhance CDC triggered by daratumumab and isatuximab in MM cells (MOLP8, EJM, and MM.1 R) and other B-cell malignancies (Daudi and SU-DHL-8) by interfering with the complement inhibitors, CD46 and CD59. Here, CD59 is linked to Miyoshi myopathy.